Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

International Journal of STD and AIDS

Volumn 9, Issue 12, 1998, Pages 751-755

  Fife, Kathryn ^a,b   Howard, Mark R ^c   Gracie, Fiona ^b   Phillips, Robert H ^b   Bower, Mark ^a,b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

AIDS; Human herpesvirus 8; Kaposi's sarcoma; Kaposi's sarcoma herpes virus; Thalidomide

Indexed keywords

HYPNOTIC SEDATIVE AGENT; THALIDOMIDE; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; KAPOSI SARCOMA; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031675320     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981921512     Document Type: Article

References (28)

1. Evans L, Itri L, Campion M, et al. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 1991;10:39-50
2. Cai J, Masood R, Lin G, et al. Retinoic acids inhibit AIDS Kaposi's sarcoma tumour cell growth in vitro and in vivo. Blood 1992;80(suppl 1):327A
3. Harris PJ. Treatment of Kaposi's sarcoma and other manifestations of AIDS with human chorionic gonadotropin. Lancet 1995;346:118-19
4. Bower M, Fife K, Nelson M, Youle M. Human chorionic gonadotropin for AIDS-related Kaposi's sarcoma. Lancet 1995;346:642
5. Bower M, Fife K, Landau D, et al. Phase II trial of 13-cis-retinoic acid for poor risk HIV associated Kaposi's sarcoma. Int J STD AIDS 1997;8:518-21
6. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13:1966-74
7. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9
8. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995;332:1181-5
9. Whitby D, Howard MR, Tenant Flowers M, et al. Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802
10. Makonkawkeyoon S, Limson Pobre RN, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8
11. Oxholm A. Epidermal expression of interleukin-6 and tumour necrosis factor-alpha in normal and immunoinflammatory skin states in humans. APMIS Suppl 1992;24: 1-32
12. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 1988;242:426-30
13. Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R. Culture and properties of cells derived from Kaposi's sarcoma. J Immunol 1991;146:2972-6
14. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80
15. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
16. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37
17. Youle M, Hawkins D, Gazzard B. Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet 1990;335:1591
18. Soler R, Howard M, Brink N, et al. Regression of acquired immunodeficiency syndrome-related Kaposi's sarcoma during thalidomide therapy. Clin Infect Dis 1996;23:501-3
19. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866-9
20. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989;7:1201-7
21. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: (Offset publication No. 48), 1979
22. Simmonds P, Balfe P, Peutherer J, et al. Human immunodeficiency virus infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers, J Virol 1990;64:864-72
23. Howard M, Whitby D, Bahadur G, et al. Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS 1997;11:F15-F19
24. Spector S, Merrill R, Wolf D, Danker W. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Micro 1992; 30:2359-65
25. Gill P, Wernz J, Scadden J, et al. Randomized phase III Trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64
26. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20
27. Wells L, Little R, Wyvill K, et al. Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS). J AIDS Hum Retrovir 1997;14:A20
28. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9